Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can bevacizumab eye injections hold up over years of Real-World use?

NCT ID NCT03211741

NEW Disease control Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers at a Belgian hospital are tracking how well bevacizumab eye injections work and how safe they stay over the long term in adults with abnormal blood vessel growth in the retina or macular edema. The study follows 583 participants who receive the drug directly into the eye. Doctors regularly check vision, eye pressure, retinal thickness, and side effects to compare real-world results with those from earlier controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bevacizumab, a drug given as an injection into the eye
What this could lead to
If the approach holds up, doctors could gain clearer guidance on how well bevacizumab eye injections work and stay safe over years of real-world use.
What could go wrong
This is an observational study, not a controlled experiment, so results may reflect the patients and practices at one center rather than proving cause and effect. Eye injections carry small risks of infection, bleeding, or increased eye pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

583 people

The number who actually took part.

Started

Nov 2013

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years of either gender 2. Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed 3. Visual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema. The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography. If both eyes are eligible for the study, both eyes can be included in the study. Exclusion Criteria: 1. Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (\> 5mIU/mL) 2. Women of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication 3. Tromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab 4. History of hypersensitivity for bevacizumab.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macular edema are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Macular Edema macular retinal edema Retinal Neovascularization

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular edema Retinal neovascularization

Contacts and locations

Locations

  • Ghent University Hospital

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.